59 results about "Pancreatic ductal adenocarcinoma" patented technology

The invention discloses a pancreatic ductal adenocarcinoma marker and a screening method thereof, which belongs to the field of clinical test and diagnosis. In view of the problem that the detection sensitivity and the detection specificity of the existing pancreatic ductal adenocarcinoma diagnosis marker are poor, serum of an early patient of early stage pancreatic duct adenocarcinoma is subjected to a trace metabolomics analysis by the high-performance liquid chromatography-tandem mass spectrometry technology, and different metabolites between normal human and the early stage pancreatic ductal adenocarcinoma patients are found. The different metabolites between normal human and pancreatic ductal adenocarcinoma patients are further analyzed by this technique to find the specific differentmetabolites C10:1 acyl carnitine and lysophosphatidyl choline LysoPC (14:0) of pancreatic ductal adenocarcinoma patients caused by cancer, i.e., the diagnostic molecules of the pancreatic ductal adenocarcinoma. According to the pancreatic ductal adenocarcinoma marker and the screening method thereof, the method can assist CA19-9 in diagnosing pancreatic duct adenocarcinoma patients, and can improve the diagnosis rate for the CA19-9 negative patients by 85%. The method is suitable for the screening of tumor markers.

The present invention provides biomarker compositions and methods for the diagnosis and prognosis of PDAC. In a particular embodiment, the invention provides methods and compositions for screening, diagnosis and prognosis of early stage, asymptomatic PDAC.

Compositions and methods for treating solid tumors such as pancreatic ductal adenocarcinoma (PDA) via interfering with the Dectin-1 signaling pathway, for example, using Dectin-1 or Galectin-9 inhibitors.

The present disclosure relates to the identification of genes and gene combinations that are correlated with patients having or being predisposed to developing pancreatic ductal adenocarcinoma (PDAC). In some instances, methods herein utilize panels of 5 or 10 genes to accurately diagnose PDAC, determine the likelihood of developing PDAC, or determine the severity / stages of PDAC. These panels may be used in a molecular diagnostic test.

The invention related to biomarkers, a method and a kit for early diagnosis of pancreatic cancer, in particular of pancreatic ductal adenocarcinoma (PDAC); and to biomarkers, a method and a kit or device for predicting or prognosticating an individual's response to combination treatment with a nucleoside analogue (preferably gemcitabine) and with a growth factor receptor (preferably erlotinib) in patients with pancreatic ductal adenocarcinoma.

The invention relates to the technical field of medical biological detection, and particularly provides a plasma exosome miRNA marker suitable for pancreatic ductal adenocarcinoma diagnosis and prognosis and application of the marker in preparing a diagnosis reagent or kit for pancreatic ductal adenocarcinoma. The bio-marker which has high diagnosis and differential diagnosis value for the pancreatic ductal adenocarcinoma is found for the first time, and the bio-marker comprises plasma exosome miRNA-95-3p, miRNA-26b-5p and miRNA-335-5p. By means of development and application of the miRNA marker and the diagnosis kit, more precise diagnosis is made for the pancreatic ductal adenocarcinoma, especially, the marker and the diagnosis kit assist clinicians in differential diagnosis of the pancreatic ductal adenocarcinoma and chronic pancreatitis, meanwhile, prognosis of patients is evaluated, and a foundation is laid for the clinicians to accurately grasp the illness states of the patientsand for improving the clinical treatment effect.

The invention discloses an antibody composition for detecting pancreatic duct adenocarcinoma immunohistochemical marker protein compositions and application of the antibody composition. The pancreatic duct adenocarcinoma immunohistochemical marker protein compositions comprise TIMP1 and CD82. The antibody composition for detecting the protein compositions comprises monoclonal antibodies of the TIMP1 and monoclonal antibodies of the CD82. The antibody composition and the application have the advantages that the TIMP1 / CD82 compositions are used as novel pancreatic duct adenocarcinoma markers, the antibody composition can be widely used in disease identification and diagnosis and prognosis monitoring of pancreatic duct adenocarcinoma, and gaps on immunohistochemical detection in the two aspects can be filled.

The invention discloses a pancreatic duct adenocarcinoma related tumor marker LINC01133, and application of a kit for detecting expression level of LINC01133 in the detection and diagnosis of pancreatic duct adenocarcinoma or patient prognostic evaluation. The expression level of LINC01133 is closely related to the clinical pathological parameters of pancreatic duct adenocarcinoma and the patientprognosis, and can be adopted as a specific tumor marker in pancreatic duct adenocarcinoma detection and a prognostic indicator, and thus is of an important clinical value.

The present invention relates to miRNA biomarkers for use in the diagnosis of pancreatic diseases, in particular pancreatic cancers and pre-cancerous diseases, such as pancreatic ductal adenocarcinoma (PDAC), in particular the early detection of PDAC. The miRNA biomarkers are miR-143, miR-223, miR-204, miR-30e, miR-26a, miR-30a, miR-30b and miR-106b. They may be combined with protein biomarkers. The present invention also provides methods of diagnosis and treatment of PDAC and related diseases, and kits for the early detection of PDAC based on the expression levels of the biomarkers in biological samples, in particular urine samples.

The application relates to methods based on modulating pancreatic and / or gastrointestinal microbiota and related antifungal compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.

The invention discloses a method for constructing a pancreatic cancer cell line by positive expression of Chinese B7-H5. The method comprises the following steps of 1, collecting of a specimen; 2, preparing of an Organoid type organ complete culture medium; 3, digestion of tissues; 4, constructing and culture of Organoid type organs of pancreatic cancer; 5, cell generation pass and culture. The method has the beneficial effects that the biology features of the constructed Chinese pancreatic cancer cell line sipanc-1076 are used as pancreatic ductal adenocarcinoma; the particular characteristicof positive expression of B7-H15 which does not exist in other commercialized human pancreatic cancer cell lines is realized; the tumor forming property is good; the method can be applied to the study on tumor immune escape of pancreatic cancer, analysis of related genealogy of Chinese pancreatic cancer, and the like.

The invention discloses a nano-drug and a preparation method thereof and application of the nano-drug in treatment of pancreatic ductal carcinoma. Specifically, after a nano drug NPUNC0638 is preparedby encapsulating a compound UNC0638 with a nano material (NP) Cys-8E, the nano drug NPUNC0638 can target a tumor part of pancreatic cancer, and has better drug delivery capacity for pancreatic ductaladenocarcinoma cells that do not respond to traditional drugs, and thus the treatment effect of the compound UNC0638 is obviously improved. The nano drug NPUNC0638 can induce pancreatic ductal adenocarcinoma cell apoptosis, and meanwhile, the nano drug NPUNC0638 can prevent UNC0638 from acting on normal cells, so that the toxic and side effects of the nano drug are reduced. The nano-drug NPUNC0638 has the advantages of being capable of targeting pancreatic ductal adenocarcinoma, small in side effect and the like, and has a good application prospect and a wide development space in the field ofclinical treatment of pancreatic ductal adenocarcinoma.

The invention discloses application of crude extract of radix tetrastigme to preparation of a chemotherapeutic medicament for inhibiting the pancreatic cancer. The invention further discloses a medicament for inhibiting the pancreatic cancer. The medicament comprises one or more of four components as follows: a component-1 (10% (1-2) EtOH extract), a component-2 (10% (-3) to 30%(1-2) EtOH extract), a component-3(30%(-1) to 50%(-1) EtOH extract) and a component-4 (50%(-2) to 95%(-2) EtOH extract). The invention further discloses application of the crude extract of the radix tetrastigme in the aspect of inhibiting the pancreatic cancer. The application comprises the following process of: respectively implanting four types of pancreatic ductal adenocarcinoma (PDAC) cells into a 96-hole plate;carrying out cell adherence, and respectively adding four components of the crude extract of the radix tetrastigme; carrying out shooting under a fluorescence microscope; and measuring a cell survival rate by CCK-8. The invention additionally further provides a method for acquiring the crude extract of the radix tetrastigme. Application of the radix tetrastigme, which is disclosed by the invention, provides a new treatment target for the chemotherapeutic medicament and a treatment medicament for the pancreatic cancer.

The invention provides an application of USP 49 (ubiquitin-specific protease 49) in preparation of a drug for preventing or treating pancreatic ductal adenocarcinoma. An amino acid sequence of the USP 49 is represented as SEQ ID NO:1. The deubiquitinating enzyme USP49 interacting with FKBP5 protein is provided, a degradation and stabilization mechanism of the FKBP5 protein as well as molecular regulation for an FKBP5-AKT pathway by the deubiquitinating enzyme USP49 is determined, the function and the molecular mechanism of the pathway in the occurrence and development processes of pancreatic ductal adenocarcinoma are provided, new basis is provided for treatment of pancreatic ductal adenocarcinoma, and USP49 has direct guidance significance for personalized medical treatment of pancreatic ductal adenocarcinoma.

This invention relates to a novel approach for the identification and stratification of subtypes of cancer, particularly pancreatic ductal adenocarcinoma (PDAC). The invention furthermore relates to a novel approach with respect to the treatment of cancer, particularly pancreatic ductal adenocarcinoma (PDAC).

The invention discloses an application of TRIM31 inhibitor magnetic targeting drug-loaded microspheres in preparation of drugs for inhibiting the proliferation ability of PDAC. With the correlation between TRIM31 and the proliferation of the pancreatic ductal adenocarcinoma cell, the TRIM31 inhibitor magnetic drug-loaded microspheres as effective ingredients are made into the drugs, and the drugshave a significant inhibitory effect on the proliferation of the pancreatic ductal adenocarcinoma cell.

The invention discloses application of p38 gamma in preparation of a pancreatic cancer prognosis diagnostic reagent. The inventor finds that expression of p38 gamma in cancer tissues of a pancreatic cancer patient is remarkably higher than that of p38 gamma in normal tissues, the expression level of p38 gamma is gradually increased along with disease progression, and the high expression of p38 gamma is related to adverse prognosis of the patient. A pancreatic duct adenocarcinoma animal model K-RasG12D-p53R172H-Pdx-Cre (KPC) is constructed as a control group for research. A pancreatic ductal epithelial cell p38 gamma knockout pancreatic cancer animal model (KPC-p38 gamma-KO) is constructed as an experimental group by applying a Cre / LoxP technology. The p38 gamma knockout is found to be capable of remarkably reducing the size of a tumor and prolonging the lifetime of KPC mice. The median survival time of the mice in the KPC group is 160 days, most KPC-p38 gamma-KO mice still survive in the statistical time, and the median survival time is longer than 300 days. A further experimental result shows that high expression of p38 gamma can promote invasion and metastasis of a pancreatic cancer. Therefore, p38 gamma can well determine the risk and prognosis of the pancreatic cancer.

Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them.

The present invention provides novel human protein antigens and related antibodies that have been identified as being specifically expressed in association to human Pancreatic Ductal Adenocarcinoma (PDA). In particular, novel phosphorylated isoforms of alpha-enolase have been identified in transformed cell lines of pancreatic origin and antibodies binding such isoforms are specifically present in the sera of PDA patients. These proteins and antibodies can be useful for the diagnosis and the treatment of PDA and other cancers having common molecular features.

This invention relates to novel approaches for the identification and stratification of subtypes of pancreatic ductal adenocarcinoma (PDAC), in particular to novel PDAC subtype-specific markers, and to diagnostic kits comprising reagents for detecting said markers.

The invention relates to biomarkers, a method and a kit for early diagnosis of pancreatic cancer, in particular of pancreatic ductal adenocarcinoma (PDAC); and to biomarkers, a method and a kit or device for predicting or prognosticating an individual's response to combined treatment with a nucleoside analogue (preferably gemcitabine) and a growth factor receptor (preferably erlotinib) in patients with pancreatic ductal adenocarcinoma.

The invention discloses a Chinese pancreas cancer cell line sipanc-187 establishment method. The method includes the following steps: 1. specimen acquisition; 2. tissue digestion; 3. PDX nude mouse tumor-bearing; and 4. tumor cell culture and passage. The beneficial effects of the invention are that a Chinese pancreas cancer cell line sipanc-187 established according to the invention is biologically characterized by pancreatic ductal adenocarcinoma, wherein the Chinese pancreas cancer cell line sipanc-187 has good tumorigenicity and certain medicine resistance. The Chinese pancreas cancer cellline sipanc-187 can be greatly applied to research of pancreas cancer tumors and a chemotherapy medicine-resistance mechanism, pedigree analysis of Chinese pancreas cancer related genes, and the like.

The application relates to methods based on modulating mammalian intestinal and / or pancreatic microbiota and related probiotic, prebiotic, and anti-bacterial compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.